ARTICLE | Emerging Company Profile
SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease
SparingVision prepares to enter the clinic in 2H21 with a €44.5M series A tranche and new CEO
October 24, 2020 1:53 AM UTC
SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna.
The Paris-based company announced a €44.5 million ($52.8 million) series A tranche Wednesday led by 4BIO Capital and UPMC Enterprises, with participation from Jeito Capital, Ysios Capital, Bpifrance and Foundation Fighting Blindness. The latter two participated in the round’s first €15.5 million ($16.4 million) tranche in 2016...